Danaher Co. (NYSE:DHR) Shares Purchased by Quilter Plc

Quilter Plc raised its stake in Danaher Co. (NYSE:DHR) by 1.6% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 59,059 shares of the conglomerate’s stock after buying an additional 927 shares during the quarter. Quilter Plc’s holdings in Danaher were worth $14,756,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Oak Thistle LLC acquired a new stake in Danaher during the 2nd quarter valued at $363,000. Caden Capital Partners LP lifted its stake in shares of Danaher by 12.4% in the fourth quarter. Caden Capital Partners LP now owns 139,068 shares of the conglomerate’s stock valued at $32,172,000 after buying an additional 15,313 shares during the period. JARISLOWSKY FRASER Ltd grew its holdings in shares of Danaher by 10.8% during the 4th quarter. JARISLOWSKY FRASER Ltd now owns 572,858 shares of the conglomerate’s stock worth $132,524,000 after purchasing an additional 55,908 shares in the last quarter. HighPoint Advisor Group LLC acquired a new position in shares of Danaher in the 4th quarter valued at $2,614,000. Finally, Norden Group LLC acquired a new position in Danaher in the first quarter worth about $4,151,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Danaher news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the transaction, the senior vice president now directly owns 4,212 shares in the company, valued at $1,130,374.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the transaction, the senior vice president now owns 4,212 shares in the company, valued at $1,130,374.44. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Rainer Blair sold 9,007 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the sale, the chief executive officer now directly owns 97,983 shares in the company, valued at $27,435,240. The disclosure for this sale can be found here. In the last quarter, insiders sold 39,659 shares of company stock valued at $11,042,433. Company insiders own 11.10% of the company’s stock.

Analysts Set New Price Targets

DHR has been the topic of a number of research analyst reports. Royal Bank of Canada restated an “outperform” rating and set a $300.00 price target on shares of Danaher in a research report on Friday, September 6th. TD Cowen increased their target price on shares of Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a report on Wednesday, July 24th. StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Leerink Partners upped their price objective on Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. Finally, Jefferies Financial Group initiated coverage on shares of Danaher in a research report on Monday, June 3rd. They set a “buy” rating and a $295.00 price objective for the company. Seven equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and an average price target of $278.94.

Danaher Trading Up 0.6 %

NYSE:DHR opened at $274.25 on Monday. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $198.07 billion, a P/E ratio of 46.48, a P/E/G ratio of 4.48 and a beta of 0.83. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $281.70. The company has a fifty day moving average of $264.55 and a 200 day moving average of $256.51.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, beating the consensus estimate of $1.57 by $0.15. The business had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The company’s revenue for the quarter was down 2.9% on a year-over-year basis. During the same quarter last year, the firm posted $2.05 earnings per share. On average, research analysts predict that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.39%. The ex-dividend date is Friday, September 27th. Danaher’s payout ratio is presently 18.31%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.